文章核心观点 - 第三季度医药和生物技术行业的财报季即将到来,多家大型制药公司将陆续公布业绩 [1] - 医药/生物技术行业属于医疗行业,包括制药/生物技术公司和通用公司以及医疗器械公司 [2] - 医疗行业第三季度整体业绩预计将同比增长3.5%,收入预计将同比增长8.8% [3] 公司业绩总结 辉瑞 - 辉瑞业绩稳健,连续4个季度超预期 [5] - 第三季度辉瑞的新冠产品销售预计有所下降,但非新冠业务收入有所改善 [7][8] 礼来 - 礼来业绩稳健,连续4个季度超预期 [9] - 第三季度礼来的重点新药如Mounjaro和Zepbound需求强劲,带动收入增长 [10] 艾伯维 - 艾伯维业绩出色,连续4个季度超预期 [11] - 第三季度艾伯维的新药如Rinvoq、Skyrizi等销售强劲,但Humira和Imbruvica销售有所下降 [12] 默克 - 默克业绩稳健,连续4个季度超预期 [13] - 第三季度默克的重磅产品Keytruda销售有所增长 [14] Bristol Myers Squibb - Bristol Myers Squibb业绩出色,连续4个季度超预期 [15] - 第三季度Bristol Myers Squibb的重点产品如Opdivo、Orencia等销售有所增长 [16][17]

Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease Acquisition also allows AbbVie to utilize Aliada's novel blood-brain barrier (BBB)-crossing technology to enhance discovery and development efforts across neuroscience NORTH CHICAGO, Ill. and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotech ...

These healthcare stocks have fantastic dividend track records.In the immortal words of the late, great entertainer Prince, forever "is a mighty long time." For investors, though 15 to 20 years can practically feel like forever. It can be hard to find stocks you'll feel comfortable holding onto for that long.However, three Motley Fool contributors think they've identified excellent dividend growth stocks you can buy and hold forever (or at least, the investing version of forever): Abbott Laboratories (ABT -1 ...

In its upcoming report, AbbVie (ABBV) is predicted by Wall Street analysts to post quarterly earnings of $2.92 per share, reflecting a decline of 1% compared to the same period last year. Revenues are forecasted to be $14.28 billion, representing a year-over-year increase of 2.5%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company reveals ...

AbbVie (ABBV) is set to report third-quarter earnings on Oct. 30, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.28 billion and $2.93 per share, respectively.The company’s earnings estimates have declined from $10.87 per share to $10.86 for 2024 in the past 60 days. During the same timeframe, estimates for 2025 have increased from $12.09 to $12.10. Image Source: Zacks Investment ResearchStay up-to-date with all quarterly releases: See Zacks Earnings Calendar.AB ...

These stocks yield between 2.8% and 3.3% in dividends. Dividend stocks can be valuable investments for retirees who want a consistent stream of income flowing into their portfolio on a regular basis. And stocks that increase their payouts can be especially valuable, as the rising dividend income can help them offset the effects of inflation. In addition, stocks that don't have a high degree of volatility can also minimize the overall risk for retirees and other risk-averse investors. Three stocks that check ...

AbbVie (ABBV) ended the recent trading session at $189.65, demonstrating a +0.94% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.22%. Meanwhile, the Dow lost 0.33%, and the Nasdaq, a tech-heavy index, added 0.76%.Shares of the drugmaker witnessed a loss of 1.77% over the previous month, beating the performance of the Medical sector with its loss of 3.79% and underperforming the S&P 500's gain of 1.47%.The investment community will be closely ...

 Companies will discover and develop novel targets for the potential treatment of neuropsychiatric conditions New discovery program builds upon nearly two decades of partnership between AbbVie and Gedeon RichterNORTH CHICAGO, Ill. and BUDAPEST, Hungary, Oct. 24, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. This collaboratio ...

关于AbbVie公司 - AbbVie下周将公布第三季度财报[1] - 预计将延续上半年的趋势实现营收和利润超出预期以及全年前景改善[1] 关于Growth Stock Forum - 专注于有吸引力的风险回报情况并密切跟踪投资组合和观察名单中的股票[1] - 有15 - 20个定期更新的模型投资组合[1] - 有多达10个预计在当年表现良好的精选股票列表[1] - 提供针对短期和中期走势的交易思路并设有社区对话和问答[1]

Wall Street expects a year-over-year decline in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on October 30, 2024, might help the stock move higher if these key numbers are better than expec ...